Search
Apatorsen
go.drugbank.com/drugs/DB06094InvestigationalApatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers
Etiprednol dicloacetate
go.drugbank.com/drugs/DB05442InvestigationalEtiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease. … Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture
Oxandrolone
go.drugbank.com/drugs/DB00621ApprovedInvestigationalA synthetic hormone with anabolic and androgenic properties.
Zinc cation
go.drugbank.com/drugs/DB14532InvestigationalSynonyms: Zinc(II), Zinc ionCategories: Decreased Copper Ion AbsorptionGlyceraldehyde-3-Phosphate Dehydrogenase
go.drugbank.com/drugs/DB17012ExperimentalCategories: Oxidoreductases Acting on Aldehyde or Oxo Group DonorsItolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnUnlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … Lumefantrine Co-Artemether is a tablet formulation of artemether and lumefantrine, a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated
Razuprotafib
go.drugbank.com/drugs/DB16353InvestigationalRazuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. … [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Azelnidipine
go.drugbank.com/drugs/DB09230InvestigationalIt has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379]. … Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.
International brands: Rezaltas LD